Simplex Castings Regulatory Approval

Simplex Castings Management Change

Simplex Castings disclosed that CFO Rajesh Kumar Acharya resigned for medical reasons, effective close of business on 13 November 2026. The filing is a Regulation 30 KMP cessation intimation with the resignation letter attached.

Simplex Castings Preferential Issue

Simplex Castings allotted 5,94,901 equity shares and 1,63,809 convertible warrants on a preferential basis to non-promoters. The total issue value is about Rs 7.97 Crore.

Value

₹7.97 Cr

Simplex Castings Preferential Issue

Simplex Castings obtained BSE in-principle approval for a preferential issue of shares and warrants. Priced at not less than ₹105, the issue is worth about ₹99.71 crore.

Value

₹99.71 Cr

Simplex Castings Board Meeting Date

Simplex Castings has scheduled a board meeting for November 13, 2026, to consider its unaudited results for the quarter and half-year ended September 30, 2026. The trading window stays closed until 48 hours after the results are declared.

Simplex Castings Other Announcement

Simplex Castings Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by regulatory norms.

Simplex Castings Preferential Issue

Simplex Castings Ltd shareholders approved the preferential issue of 44.90 lakh equity shares and 50.05 lakh convertible warrants. The EGM also cleared an increase in authorized share capital.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.